Aktiesnakken — Juni 2010
-
specielt når man tænker på genmabs pressede situation og deres kurs
-
det kan jo også true gsk hvis en ny køber pludseligt byder
-
at der IKKE er øjekast
-
men de kan jo også blive overhalet indenom af en konkurrent. Hvis du er lille partner med en stor, vil den dialog være ret naturlig når
-
den lille kommer i problemer
-
nej de kan blokere en afnotering
-
men freefloat er 100% og gsk har 9,9%
-
nej
-
varnæs kaldte bunden munk
-
AU kom med ny anbefaling
-
hya
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind